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Summary Eleven patients suffering from intra-abdominal malignancy were treated with various doses of intraperitoneal mitomycin C
adsorbed onto activated carbon particles. Seven of the patients underwent resection of their primary gastric tumour and all developed
potentially life-threatening severe complications that proved to be fatal in four patients. The pattern of complications seen in these patients
was unusual in patients undergoing gastrectomy and must be presumed to be secondary to the intraperitoneal mitomycin C. Intraperitoneal
mitomycin C at a dose of 25 mg and 50 mg in the presence of an anastomosis or other suture line does not appear to be safe.
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The prognosis for patients with gastric adenocarcinoma is poor,
with a 5-year survival of 16.5% (Faivre et al, 1985). Atpresent, the
only chance of cure is by surgery, and around 50% of all patients
presenting with gastric cancer will have tumours that are suitable
for curative resection. However, up to 50% ofpatients undergoing
potentially curative resection will relapse and die of recurrent
disease within 5 years (Siewert et al, 1993).
Relapse after surgery is most commonly due to nodal or peri-
toneal recurrence (Iwanaga et al, 1978). In tumours that have
already breached the gastric serosa (T3), peritoneal recurrence is
the commonest cause of death (Gunderson and Sosin, 1982;
Landry et al, 1990). Five-year survival drops very markedly once
the serosa is breached, emphasizing t"he importance ofthis type of
tumour spread in gastric cancer (McCulloch, 1995). Peritoneal
recurrence is assumed to be due to microscopic tumour deposits
shed either before surgery or during surgery.
Adjuvant therapy is aimed ateradicating the malignant cells that
have disseminated before or at the time of surgery. It is generally
accepted that those treatments that are active in advanced disease
would have the best chance ofsuccess in an adjuvant setting.
Several studies of adjuvant chemotherapy in patients with
gastric cancer have been performed (Bleiberg et al, 1992) but
almost all ofthem have failed to show a survival advantage in the
treated groups.
However, in 1992 Hagiwara et al reported very promising
results in a small randomized study using mitomycin C adsorbed
onto activated charcoal particles (M-CH) administered into the
peritoneal cavity of gastric cancer patients before surgical closure
after gastrectomy. The study was restricted to tumours reaching
the gastric serosa (T3) and demonstrated a 41.7% improvement in
survival at 3 years with minimal toxicity.
Received 15 January 1997
Revised20 May 1997
Accepted2 June 1997
Correspondence to: SS Ubhi
This encouraging study prompted us to investigate the efficacy
ofmitomycin C adsorbed onto activated carbon particles in British
patients with gastric cancer and pseudomyxoma. We began the
study in our centres with a view to proceeding to amulticentre trial
in the UK.
PATIENTS AND METHODS
Approval for the study was obtained from ethics committees at
both ofthe study centres. Patient details are summarized inTable 1.
All patients had normal pretreatment blood count (white cell
count > 4 x 106 mi-X; platelet count > 120 x 106 mlF; haemato
crit > 30%), no evidence of major organ failure (normal cardiac,
pulmonary, renal and hepatic function) and an ambulatory perfor-
mance status > 80%.
Treatment comprised mitomycin C (supplied by Kyowa Hakko
UK) adsorbed onto 400 mg activated carbon particles suspended
in 150 ml of sterile physiological saline. Carbon particles were
supplied by Dr Hagiwara. Particle size and adsorption characteris-
tics of the carbon particles were confirmed by the pharmacy
departments at each of the study centres. The drug and carbon
particles were prepared in the hospital pharmacy according to the
technique described by Hagiwara et al (1992) and were made up
on the day of use. The preparation was shaken vigorously for
10-20 min before use and was introduced into the peritoneal
cavity during the operation and was carefully dispersed. Care was
taken to avoid anastomotic lines and to avoid leaving puddles of
the preparation in undrained areas. All abdominal drains were
clamped for the first 2 h after the operation.
The authors had visited Kyoto, Japan and were personally
instructed by members of the Kyoto team in the techniques for
administration ofM-CH.
Patients were initially treated using 50 mg of mitomycin C.
However, as severe complications were experienced with this
dosage (see below), the protocol was modified and subsequent
patients were treated with lower doses of mitomycin C. One
patient was treated with a very low dose ofmitomycin C (8 mg) as
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Table 1 Details and results of treatment of patients treated with mitomycin C
Age Sex Diagnosis Stage Surgery Mitomycin C Complications Complications Time to death
dose fatal? (days)
52 Male Gastric T2PON1MO D2 total 50 mg Pancreatic Yes 35
adenocarcinoma abscess and MOF
71 Male Gastric T2PON2MO D2 distal 25 mg Anastomotic leak No N/A
adenocarcinoma
76 Male Gastric T3PON1MO D2 distal 50 mg Coeliac axis Yes 48
adenocarcinoma rupture
68 Male Gastric T2PON2MO D2 distal 50 mg Coeliac axis Yes 29
adenocarcinoma rupture and MOF
58 Male Gastric T3PON2M0 D2 total 50 mg Anastomotic leak Yes 35
adenocarcinoma and MOF
69 Male Gastric T3PON4M0 Dl distal 50mg Duodenal stump No N/A
adenocarcinoma leak
48 Male Gastric T4P3N2MO Dl distal 25 mg Enteric fistula No N/A
adenocarcinoma palliative
51 Male Gastric T3P3NxMx Laparoscopy 25 mg Pain No N/A
adenocarcinoma
70 Female Gastric T4P3N2MO Laparotomy 25 mg Pain No N/A
adenocarcinoma
51 Male Pseudomyxoma TxP3NxMx Laparotomy 8 mg Pain No 119
63 Male Pseudomyxoma TxPxNxMx Laparoscopy 30 mg Nil No N/A
MOF, multiple organ failure.
we were physically unable to instil any more of the preparation
into the peritoneal cavity.
In this sense, this study was not aformal phase I study with dose
escalation, depending on outcome, but a study that used different
doses ofthe M-CH preparation.
RESULTS
The patient details and post-treatment course are summarized in
Table 1.
Eleven patients were treated with various doses ofmitomycin C.
Nine patients had gastric adenocarcinoma and two had
pseudomyxoma peritonei. Seven of the patients with gastric
adenocarcinoma underwent resection: six potentially curative
resection and one palliative resection. Four of the treated patients
with advanced malignancy hadeither a laparoscopy or laparotomy
alone with no resection.
All seven patients who had gastric resection developed severe
complications, including leucocytopenia (< 3 x 109 1-1), thrombo-
cytopenia (< 100 x 109 1-'), multiple organ failure, pancreatic
abscess, suture line dehiscence and coeliac axis rupture. In four of
these patients the complications were fatal (see Table 1). Some of
the complications seen in these patients, particularly coeliac axis
rupture, are notcommonly seen in patients undergoing gastrectomy.
DISCUSSION
The 41.7% 3-year survival advantage reported by Hagiwara after
intraperitoneal M-CH treatment suggested that an effective treat-
ment hadbeen found foradisease with apoorprognosis. The treat-
ment had a number of attractive novel features. It appeared to act
as a slow-release preparation, thus increasing the area under the
curve to which tumour cells would be exposed, and reducing acute
toxicity from high drug concentrations (Cunliffe and Sugarbaker,
1989). This feature also circumvented some of the difficult
pharmacokinetic problems that have dogged more conventional
approaches to intraperitoneal chemotherapy (Markman, 1991).
The treatment also appeared to be cheap, simple to administer and
relatively free oftoxicity.
The range and frequency ofcomplications reported by Professor
Takahashi and his colleagues in Kyoto, Japan were far less than
those seen in our patients. They found leucocytopenia occurred in
6.3% ofpatients, thrombocytopenia in 10.4%, anastomotic leakage
in 6.3% and there were no treatment related deaths in their series
(Takahashi et al, 1995). Our experience in this small series was
much less encouraging.
All ofourtreated patients who had agastric resection went on to
develop severe life-threatening complications and in four out of
the seven resected patients the complications were fatal.
The frequency and nature ofcomplications in the treated patients
suggest that they were most likely to be chemotherapy related. The
types ofcomplications were unusual; three patients developed fatal
multiple-organ failure without clear evidence of a major initiating
septic or hypotensive event and in two patients there was fatal
delayed rupture ofthe coeliac axis. In contrast to the complications
seen in the patients undergoing resection, patients who underwent
laparoscopy or laparotomy alone did not develop significant
treatment-related toxicities. Ourconclusion from this limited series
ofpatients is that the administration ofintraperitoneal mitomycin is
not safe in the presence ofan anastomosis or other suture line.
Why should our British patients develop such severe complica-
tions compared with the Japanese patients?
First, we are treating patients who are on average 10 years older
than the Japanese patients (65 years compared with 55.7 years).
British Journal ofCancer(1997) 76(12), 1667-1669 0CancerResearch Campaign 1997Intraperitoneal M-CHin GI malignancy 1669
Even although the treated patients satisfied strict inclusion criteria
it is probable that our older patients are less able to tolerate the
treatment than the youngerJapanese patients.
Second, it has been suggested that British patients are morpho-
logically different from their Japanese counterparts. The shape of
the average British patient may lead to a greater likelihood of the
mitomycin preparation forming pools. This may lead to higher
levels of the drug being absorbed into the systemic circulation,
perhaps accounting forthehigh incidence ofmultiple organ failure
and may also lead to high concentrations of the drug around the
coeliac axis and suture lines, which may lead to impaired healing
at these sites. The more atherosclerotic arteries ofthe older British
patients would appear to be at greater danger than those of the
younger Japanese patients after lymphadenectomy around them
followed by exposure to mitomycin C.
Although gastric cancer surgery can produce serious complica-
tions, both centres involved in this work have reported satisfactory
morbidity and mortality for this type ofsurgery. Neither has previ-
ously experienced complications of the specific types discussed
above in patients undergoing surgery alone.
Measurement ofplasma levels ofmitomycin C may have helped
to explain the possible toxic effects of the treatment.
Unfortunately, they were notperformed routinely in our study. Our
results have convinced us that intraperitoneal M-CH as used in this
study is unsafe as a surgical adjuvant treatment in British patients
with gastric cancer. We understand that a randomized trial of the
M-CH treatment is under way, but no morbidity or mortality
reports are available.
It has recently been reported that mitomycin C adsorption to
activated charcoal in vitro is extremely variable, but can be made
reproducible by the addition ofa wetting agent (Shah et al, 1997).
The attractions ofthe concept ofa slow-release delivery system
for intraperitoneal chemotherapy remain valid in a disease in
which recurrence is predominantly intraperitoneal, and in which
systemic chemotherapy has little to offer. In view bf our findings,
however, this approach may need to be re-explored using different
drugs or vehicles.
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